At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into ...

A Centers for Disease Control and Prevention webpage that previously stated "Vaccines do not cause autism" has been changed ...

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The new line of credit could ease pressure on the money-losing vaccine maker as it tries to chart its post-pandemic future.

Malone, known for promoting disputed claims about COVID vaccines, will serve in an unpaid role focused on federal policy ...

Lots more details about the fallout from STAT’s John Wilkerson. Read more here.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...

Moderna (MRNA) stock gains as the firm projects 10% growth for next year ahead of the consensus as it plans to conduct the ...

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 ...